DPP-4抑制剂作用于非酒精性脂肪肝发病机制的研究进展

Research advances in the role of DPP4 inhibitor in the pathogenesis of nonalcoholic fatty liver disease

摘要:

非酒精性脂肪肝是指除酒精和药物、遗传疾病等其他明确因素之外所诱导的肝脏病变，它的发病机制可能是胰岛素抵抗、脂代谢紊乱、氧化应激等。DPP-4抑制剂等降糖药物对其具有保护作用，其作用机制可能是改善胰岛素抵抗、抑制脂质合成、抑制炎症反应等。非酒精性脂肪肝发病率逐年上升，但临床上仍缺乏有效的干预措施，根据其发病机制需积极地寻找治疗手段。

Abstract:

Nonalcoholic fatter liver disease（NAFLD） refers to liver lesions induced by the factors other than alcohol，drugs，and hereditary diseases，and its pathogenesis may be insulin resistance，dyslipidemia，and oxidative stress. Hypoglycemic agents including DPP4 inhibitor exert a protective effect against NAFLD，possibly by improving insulin resistance and inhibiting lipid synthesis and in－flammatory response. The incidence rate of NAFLD is increasing year by year，but there are still no effective intervention measures in clinical practice. Treatment measures should be actively explored based on pathogenesis.